Pirfenidone treatment for patients with atypical liver function

Details Pirfenidone treatment for patients with atypical liver function Pirfenidone treatment for patients with atypical liver function

2009-09-03

2009-12-22

Tsang, Cecilia (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

07635707

ABSTRACT:
Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.

REFERENCES:
patent: 5310562 (1994-05-01), Margolin
patent: 5518729 (1996-05-01), Margolin
patent: 5716632 (1998-02-01), Margolin
patent: 7407973 (2008-08-01), Ozes et al.
patent: 2006/0110358 (2006-05-01), Hsu
patent: 2007/0053877 (2007-03-01), Crager et al.
patent: 2007/0054842 (2007-03-01), Blatt et al.
patent: 2007/0072181 (2007-03-01), Blatt
patent: 2007/0092488 (2007-04-01), Strieter et al.
patent: 2007/0172446 (2007-07-01), Blatt
patent: 2007/0203202 (2007-08-01), Robinson et al.
patent: 2007/0203203 (2007-08-01), Tao et al.
patent: 2008/0019942 (2008-01-01), Seiwert et al.
patent: 2008/0194644 (2008-08-01), Bradford
patent: 2008/0287508 (2008-11-01), Robinson et al.
patent: 2009/0170804 (2009-07-01), Phillips et al.
Salazar-Montes et al., Potent antioxidant role of pirfenidone in experimental cirrhosis.Eur. J. of Pharmacol.595: 69-77 (2008).
Azuma et al., Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.Am. J. Resp. Crit. Care Med.171: 1040-7 (2005).
Garcia et al., Pirfenidone effectively reverses experimental liver fibrosis.J. of Hepatol. 37: 797-805 (2002).
Lasky, Pirfenidone.IDrugs7(2): 166-72 (2004).
Dosanjh, Pirfenidone: a novel potential therapeutic agent in the management of chronic allograft rejection.Transplant. Proc.39: 2153-6 (2007).
Shi et al., Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in health Chinese volunteers.J. Clin. Pharmacol.47: 1268-1276 (2007).
Angulo et al., Pirfenidone in the treatment of primary sclerosing cholangitis.Dig. Dis. Sci.47(1): 157-61 (2002).
Senior, Monitoring for hepatotoxicity: what is the predictive value of liver “function” tests?Clin. Phamacol. Ther.85(3): 331-334 (2009).
Pirespa® package insert, Shionogi & Co., Ltd. Prepared in Oct. 2008 (1stversion).
Azemar et al., Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2.Breast Cancer Res. Treat.82: 155-164 (2003).
de Boer et al., Myelotoxicity and hepatotoxicity during azathioprine therapy.Neatherlands J. Med.63(11):444-446 (2005).
FDA, New Warning for Strattera, Dec. 17, 2004.
FDA, Questions and Answers on Ketek (telithromycin), Feb. 12, 2007 (available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107826.htm, last visited Jun. 5, 2009).
Hammoud et al., Poor tolerability to high dose PEG interferon and ribavirin in HIV/HCV coinfected patients; Initial results from a randomized multicenter trial.Hepatol. 38(4): Suppl.1 327A (2003).
Kai et al., Imatinib mesylate induced fatal hepatitis B virus (HBV) reactivation in a patient with CML.Blood104: Abstract 4677 (2004).
Ladas et al., Milk thistle is associated with reductions in liver function test (LFTs) in children undergoing therapy for acute Iymphoblastic leukemia (ALL).Blood108: Abstract 1882 (2006).
Parafon Forte® DSC (chlorzoxazone) package insert, Ortho-McNeil Pharmaceutical, Inc. Revised Aug. 2000.
Ridruejo et al., Imatinib-induced fatal acute liver failure.World J. Gastroenterol. 13(48): 6608-6611 (2007).
Scherpbier et al., Once-daily highly active antiretroviral therapy for HIV-infected children: Safety and efficacy of an efavirenz-containing regimen.Pediatrics119: e705-e715 (2007).
Tostmann et al., Antituberculosis drug-induced hepatotoxicity is unexpectedly low in HIV-infected pulmonary tuberculosis patients in Malawi.Trop. Med. International Health.12(7): 852-855 (2007).
Tracleer® Bosentan Tablets package insert, Actelion Pharmaceuticals US, Inc. Prepared Mar. 2009.
Yoshimoto et al., Transient liver injury caused by gefitinib.J. Japanese Respiratory Soc. 42(1): 56-61 (2004)—Abstract.
Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, “Report on the Deliberation Results,” (2008).

Affiliated with

Also associated with

Rating

Pirfenidone treatment for patients with atypical liver function does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pirfenidone treatment for patients with atypical liver function, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pirfenidone treatment for patients with atypical liver function will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4146405